Averaging up to 20% of weight loss, adults taking Zepbound had 25 fewer breathing interruptions each hour as they slept.

The US Food and Drug Administration approved a new indication for Eli Lilly’s formulation of tirzepatide to treat moderate to ...

The nod, just months after topline results from SURMOUNT-OSA came out, makes it the first drug approved for this indication.

If you have sleep apnea and obesity, tirzepatide Zepbound may offer relief and support weight loss. Ask your doctor if it’s a ...

The Food and Drug Administration (FDA) has approved Zepbound ® (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity.

Already established as cornerstone therapies in diabetes and obesity, GLP-1 receptor agonists have now cracked into the ...

This weight-loss drug, designed for obese patients, significantly reduces breathing disruptions and offers a new treatment ...

The Food and Drug Administration has approved Zepbound to treat obstructive sleep apnea for people who are moderately or ...

Popular weight loss drug Zepbound, which is already approved to treat obesity, now becomes the first drug to ever treat sleep ...

“Today’s approval marks the first drug treatment option for certain patients with obstructive sleep apnea,” said Sally ...

According to Statistics Canada, 25 per cent of Canadians are "dissatisfied" with their sleep. And some clinicians say the ...

Indianapolis: Eli Lilly and Company has announced the U.S. Food and Drug Administration (FDA) has approved Zepbound ...